Abstract:ObjectiveTo evaluate the shortterm efficacy and safety of concurrent chemoradiotherapy (CCRT) with paclitaxel and lobaplatin for advanced esophageal cancer. MethodsSixtyeight patients with advanced esophageal cancer were randomly divided into two groups according to random number table method: CCRT with paclitaxel and lobaplatin (TL group) and CCRT with DDP and 5Fu (PF group). The CCRT regimen included radiotherapy at a total dose of 6070 Gy, and concurrent paclitaxel 60 mg/m2 on d1, a fraction per week for 68 weeks, lobaplatin 30 mg/m2 on d2, a fraction per 3 weeks (TL group), and concurrent DDP 75 mg/m2 on d1, 5Fu 500 mg/m2, d15, CF 200 mg/m2, d15 (PF group). ResultsAll 68 patients were evaluable for response. The response rates were 73.53% in TL group and 50.00% in PF group, the median progressionfree survival were 13.0 months in TL group and 6.5 months in PF group. There were significant differences (χ2=4.023, P=0.040; χ2= 4.512, P=0.034). The incidence rates of ⅢⅣ degree nausea and vomiting, granulocytopenia and thrombocytopenia were 5.88% and 35.29%, 20.59% and 32.35%, 32.35% and 8.82%, and the differences were statistically significant (χ2=8.500, P=0.003; χ2=3.200, P=0.041; χ2=6.710, P=0.016). The incidence rates of ⅢⅣ degree esophagitis in the two groups were 11.76% and 17.65%, and there was no significant difference (χ2=1.45, P=0.493). ConclusionThe efficacy of TL group in the treatment of advanced esophageal cancer is excellent, and all toxicities are well tolerated. So this protocol may be considered a main regimen in the treatment of advanced esophageal cancer.

Key words:sophageal neoplasms,Drug therapy, combination,Paclitaxel,Lobaplatin